Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Low cost of generic medicines is a significant driver for demand, as their efficacy is at par with branded medicines

    60% confidence
  • The global Generic Drug Market will grow at a CAGR of approximately 6.55% during the forecast period from 2025 to 2034

    60% confidence
  • The global Generic Drug Market is expected to reach USD 519.11 Billion in 2025

    60% confidence
  • Asia Pacific is the second-largest market for generic medicines, driven by low disposable income and high chronic disease burden

    60% confidence
  • Oncology has emerged as the largest therapeutic application segment for generic medicines due to high global cancer prevalence

    60% confidence
  • Pure generic drugs experienced tremendous market growth due to high consumer demand and advanced manufacturing technologies

    60% confidence
  • North America is the largest regional market for generic drugs, driven by a large geriatric population with chronic diseases and the presence of key market players

    60% confidence
  • Expanding generic drug store presence in rural sectors represents a significant growth opportunity for the market

    60% confidence
  • Retail pharmacies are the largest distribution channel for generic drugs due to direct access to consumers

    60% confidence
  • Oral formulations are the leading route of administration for generic drugs and the most commonly used, including for children

    60% confidence
  • The global Generic Drug Market size was valued at approximately USD 491.35 Billion in 2024

    60% confidence
  • The global Generic Drug Market is projected to reach approximately USD 926.54 Billion by 2034

    60% confidence
  • Private medical practitioners preferring branded medicines due to higher profit margins is a key market restraint

    60% confidence
  • Lack of awareness about generic drug efficacy and absence of generic drug stores in rural areas are major market restraints

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com